Effect of intravenous application of tranexamic acid on blood loss in posterior lumbar interbody fusion

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025176

Enrollment

Unknown

Registered

2019-08-15

Start date

2019-08-14

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar spinal stenosis, lumbar disc herniation, lumbar spondylolisthesis

Interventions

A:0.9% normal saline solution without TXA

B:1.0gTXA intravenous infusion 30 minutes prior to surgery

C:1.0gTXA intravenous infusion 30 minutes prior to surgery,and the same dose of TXA was administered 3 hours later.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need posterior lumbar interbody fusion surgery for spinal diseases . 2. Normal platelet and coagulation function preoperatively. 3. Normal intravenous ultrasound in the lower extremities preoperatively. 4. To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to TXA. 2. Recent treatment with antiplatelet or anticoagulants agents within 1 week. 3. Reoperative anemia (female hemoglobin<110g/L, male hemoglobin<120g/L). 4. Blood clot events within 6 months. 5. Kidney and/or liver failure.

Design outcomes

Primary

Measure	Time frame
blood loss;postoperative drainage;the level of Hb;complications;	—

Countries

China

Contacts

Public ContactLi Hongwei

Affiliated Hospital of Xuzhou Medical University

lihongwei2000@126.com+86 18052268317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026